Here's What AstraZeneca's Recent FDA News Means for Shareholders

Here's What AstraZeneca's Recent FDA News Means for Shareholders

Source: 
Motley Fool
snippet: 
  • Tremelimumab and Imfinzi may have an addressable market in the tens of thousands of patients.
  • The potential drug pairing could top $1 billion in sales for AstraZeneca.
  • The stock seems like a good buy at this time for investors with a long-term mindset.